Management of Mitochondrial Disorders Through Increased Intestinal Fermentation and Reduced Metabolic Burden
Abstract
This proposal explores the role of the microbiome and management of mitochondrial disease. Aim 1 proposes to obtain high quality sequencing data from a mouse model of mitochondria disease at different stages of disease, as well as from animals treated with acarbose, a drug known to alter the composition of the intestinal microbiome. Aim2 explores therapeutic approaches based on alterations of the intestinal microbiomes composition or activity, either through microbiome transplantation or treatment with fermentable carbon sources or fermentation products.We have gathered most of the samples required for Aim 1 and attempted microbiome transfers in breeder animals as suggested in the original proposal. We have discovered that germ-free animals are longer lived than animals in specific pathogen free facilities. However, microbiome transfers were inconclusive. We are attempting a different strategy for the transfer experiments.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2024
- Accession Number
- AD1228215
Entities
People
- Alessandro Bitto
Organizations
- University of Washington